tislelizumab + azacitidine + lenalidomide

This is an experimental **combination therapy** involving three agents: - **Tislelizumab** is a monoclonal antibody that targets programmed cell death protein 1 (**PD-1**), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. - **Azacitidine** is a hypomethylating agent (antimetabolite), primarily used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) by inhibiting DNA methyltransferase and reactivating tumor suppressor genes. - **Lenalidomide** is an immunomodulatory agent that affects the tumor microenvironment, inhibits angiogenesis, and has direct anti-leukemic effects. This regimen has been explored in the context of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes, particularly post-allogeneic hematopoietic stem cell transplantation, where the goal is to leverage synergistic effects of epigenetic modulation, immune checkpoint inhibition, and immunomodulation. Clinical evidence mostly comes from case reports and small studies; safety concerns, especially the risk of graft-versus-host disease (GVHD), are notable when combining immune checkpoint inhibitors with these agents[2][3].

Brand names

TevimbraVidazaOnuregRevlimid

Other names

tislelizumab + azacytidine + lenalidomideTislelizumab Combinations in Refractory NKTCL